35 Result(s)

Article

Anemia diagnosis and therapy in malignant diseases: implementation of guidelines—a representative study

Anemia in cancer should be diagnosed and treated according to guideline recommendations. The implementation of ESMO and German guidelines and their effect on anemia correction was analyzed.

Hartmut Link, Markus Kerkmann, Laura Holtmann, Markus Detzner in Supportive Care in Cancer (2024)

Article

Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer

Clinical practice guidelines recommend the use of all approved granulocyte colony-stimulating factors (G-CSFs), including filgrastim and pegfilgrastim, as primary febrile neutropenia (FN) prophylaxis in patien...

Matti S. Aapro, Stephen Chaplin, Paul Cornes, Sebastian Howe… in Supportive Care in Cancer (2023)

Article

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306

Early tumor shrinkage (ETS) quantifies the objective response at the first assessment during systemic treatment. In metastatic colorectal cancer (mCRC), ETS gains relevance as an early available surrogate for ...

Felix O. Hofmann, Volker Heinemann, Melvin D’Anastasi… in European Radiology (2023)

Article

Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)

Hartmut Link in Supportive Care in Cancer (2022)

Article

Erratum zu: G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung

Hartmut Link in best practice onkologie (2022)

Article

Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections

In secondary immunodeficiency, immunoglobulin replacement therapy (IgRT) is recommended by guidelines (GL) for patients with IgG level < 4 g/l and more than 3 infections or a severe infection. IgRT may be appr...

Hartmut Link, Markus Kerkmann, Laura Holtmann in Supportive Care in Cancer (2022)

Article

G-CSF zur Prophylaxe der Neutropenie und der febrilen Neutropenie, Anämie bei Krebserkrankung

Infektionen bei neutropenischen Patienten nach Chemotherapie manifestieren sich meistens durch Fieber (febrile Neutropenie, FN). Zu den wichtigsten Determinanten des FN-Risikos gehören der Chemotherapietyp, di...

Hartmut Link in best practice onkologie (2022)

Article

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

Early results of the randomized placebo-controlled SORAML trial showed that, in patients with newly diagnosed acute myeloid leukaemia (AML), sorafenib led to a significant improvement in event-free (EFS) and r...

Christoph Röllig, Hubert Serve, Richard Noppeney, Maher Hanoun, Utz Krug… in Leukemia (2021)

Article

Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study

Lipegfilgrastim has been shown to be non-inferior to pegfilgrastim for reduction of the duration of severe neutropenia (DSN) in breast cancer patients. This open-label, non-inferiority study assessed the effic...

Hartmut Link, G. Illerhaus, U. M. Martens, A. Salar… in Supportive Care in Cancer (2021)

Article

Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany

To assess adherence to the current European Society for Medical Oncology (ESMO) clinical practice guideline on bone health in cancer patients and the German guidelines for lung, breast, and prostate cancer amo...

Hartmut Link, Ingo Diel, Carsten-H. Ohlmann, Laura Holtmann… in Supportive Care in Cancer (2020)

Article

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors

Recombinant granulocyte colony-stimulating factors (rG-CSFs), such as filgrastim, are administered to prevent complications in patients receiving chemotherapy. In Europe, a biosimilar to filgrastim, tevagrasti...

Camille N. Abboud, Nicole Lang, Henry Fung, Andreas Lammerich… in Supportive Care in Cancer (2019)

Article

G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey

Current guidelines (GL) recommend neutropenia prophylaxis with G-CSF after chemotherapy (CTX) for patients with high (≥ 20%), or, if additional risk factors are present, intermediate (≥ 10–20%) risk of febrile...

Hartmut Link, Markus Kerkmann, Laura Holtmann, Petra Ortner in Supportive Care in Cancer (2019)